BMS-986020 (AM152) sodium is a high-affinity lysophosphatidic acid receptor 1 ( LPA1 ) antagonist BMS-986020 sodium inhibits bile acid and phospholipid transporters with IC 50 s of 4.8 µM, 6.2 µM, and 7.5 µM for BSEP, MRP4, and MDR3, respectively BMS-986020 sodium has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) In Vitro BMS-986020 sodium (0.1-10 nM; pre-incubated) concentration-dependent displacement of [ 18 F]BMT-083133 binding is observed in LPA1 + cells and lung sections. At 0.1 nM, the percent displacement in healthy mice, bleomycin mice, and IPF lungs is 18%, 24%, and 31%, respectively. At 10 nM, the percent displacement is 73%, 76%, and 64%, respectively. [ 18 F]BMT-083133, a radioligand targeting LPA1 is developed as a translational research tool for assessment of lung LPA1 engagement of BMS-986020 using in vitro autoradiography (ARG) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:IC50: 4.8 µM (BSEP),6.2 µM (MRP4),7.5 µM (MDR3)
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
BMS-986020 sodium
CAS number：1380650-53-2 molecular formula：C29H25N2NaO5
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 1380650-53-2 | molecular formula | C29H25N2NaO5 |
| molecular weight | 504.51 g/mol | Exact mass | ≥98% |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
